Discovery and Preclinical Characterization of BIIB129, a Covalent, Selective, and Brain-Penetrant BTK Inhibitor for the Treatment of Multiple Sclerosis. Martin K. Himmelbauer , Bekim Bajrami , Rebecca Basile , Andrew Capacci , Teyu Chen , Colin K. Choi , Rab Gilfillan , Felix Gonzalez-Lopez de Turiso , Chungang Gu , Marc Hoemberger , Douglas S. Johnson , J. Howard Jones , Ekta Kadakia , Melissa Kirkland , Edward Y. Lin , Ying Liu , Bin Ma , Tom Magee , Srinivasa Mantena , Isaac E. Marx , Claire M. Metrick , Michael Mingueneau , Paramasivam Murugan , Cathy A. Muste , Prasad Nadella , Marta Nevalainen , Chelsea R. Parker Harp , Vatee Pattaropong , Alicia Pietrasiewicz , Robin J. Prince , Thomas J. Purgett , Joseph C. Santoro , Jurgen Schulz , Simone Sciabola , Hao Tang , H. George Vandeveer , Ti Wang , Zain Yousaf , Christopher J. Helal , Brian T. Hopkins Journal of Medicinal Chemistry（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
